Radiopharm's Cancer Pipeline Surges on Strong Data and Funding

SYDNEY, Jan. 28, 2026 – Radiopharm Theranostics has signaled a period of major clinical acceleration, reporting highly promising interim data from its lead diagnostic program and outlining significant progress across a broad pipeline of cancer-fighting agents. In its half-year financial report, the dual-listed biopharmaceutical company also revealed a fortified cash position, ensuring it is well-funded to pursue key milestones through 2027.

The announcement highlights a pivotal moment for the company as it advances multiple radiopharmaceutical assets designed to both diagnose and treat some of the most challenging solid tumors. The positive developments position Radiopharm as a notable player in a rapidly expanding and competitive field.

“2025 was a year of strong execution across our pipeline,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics, in a statement. “As we enter 2026, we remain laser-focused on advancing our radiopharmaceutical assets... we aim to deliver meaningful data from across multiple programs, expand treatment and diagnostic options for patients with solid tumors, and create long-term value for all stakeholders.”

A Potential Breakthrough in Brain Metastases Imaging

Central to the company's update is the striking interim data from the Phase 2b trial of RAD 101, a novel imaging agent for patients with brain metastases. These secondary cancers, which spread to the brain from other parts of the body, affect over 300,000 people in the U.S. annually and present significant diagnostic challenges.

The study showed that in 92% of the first twelve evaluable patients, the RAD 101 PET scan results were concordant with MRI imaging, the current standard of care. This high level of agreement meets the trial's primary endpoint and suggests RAD 101 could become a powerful new tool for detecting recurrent brain metastases. The results are consistent with earlier Phase 2a data, bolstering confidence as the company moves forward.

RAD 101, a small molecule targeting the fatty acid synthase (FAS) enzyme often overexpressed in tumors, has already received Fast Track Designation from the U.S. Food and Drug Administration (FDA), a program designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need. With enrollment in the 30-patient trial expected to conclude in the first quarter of 2026, Radiopharm is already preparing for a potential multi-center, global Phase 3 registrational trial, a critical step toward commercial approval.

A Multi-Front Assault on Aggressive Cancers

Beyond the promising diagnostic news, Radiopharm is advancing a diversified therapeutic pipeline targeting a range of aggressive cancers. The company is leveraging different platform technologies, including nanobodies and monoclonal antibodies, to deliver radioactive payloads directly to tumor cells.

Progress is particularly notable in two Phase 1 trials using nanobody technology:

• RAD 202, which targets HER2-positive tumors common in breast cancer and other malignancies, has shown a favorable safety profile and significant tumor uptake. Following a recommendation from the Data Safety and Monitoring Committee (DSMC), the trial is now escalating to a higher dose, with more comprehensive data expected in mid-2026.
• RAD 204 targets the well-known immune checkpoint PD-L1, which is implicated in non-small cell lung cancer (NSCLC), triple-negative breast cancer, and melanoma. Early data from the Phase 1 trial is encouraging: two of three patients with metastatic NSCLC in one cohort exhibited stable disease for 5.5 months, a notable improvement over the 3.5-month progression-free survival seen with the standard of care. The trial is also advancing to a higher dose level after demonstrating a reassuring safety profile with no drug-related adverse events.

Furthermore, the company is set to initiate two new Phase 1 trials in the first quarter of 2026. RAD 402, which uses the potent radionuclide Terbium-161, will be tested in patients with advanced prostate cancer. Meanwhile, enrollment is nearly complete for a Phase 1 imaging trial of RAD 301 in pancreatic cancer, with plans to advance to a Phase 2 study focusing on earlier-stage disease to address a major unmet need.

Strategic Alliances and Financial Firepower

Underpinning this ambitious clinical agenda is a robust financial and strategic foundation. Radiopharm ended the first half of fiscal 2026 with a cash balance of approximately $34.52 million. This position was significantly bolstered by a successful private placement in October 2025 that raised an additional $35 million from international and Australian investors. The company now projects a cash runway extending into 2027, providing the stability needed to see its programs through critical clinical and regulatory inflection points.

A key element of Radiopharm's strategy is its joint venture, Radiopharm Ventures, with the prestigious MD Anderson Cancer Center. This collaboration is designed to develop novel therapeutics based on intellectual property from the cancer center. Reflecting its confidence in the venture, Radiopharm recently increased its ownership stake from 75% to 87.5%.

The partnership is already bearing fruit. Its lead candidate, RV 01 (Betabart), a monoclonal antibody targeting the B7H3 protein highly expressed on tumors, received FDA clearance to begin human trials in July 2025. The company expects to dose the first patient in its Phase 1 trial in the first quarter of 2026, marking a major milestone for the joint venture.

Navigating a Red-Hot Radiopharmaceutical Market

Radiopharm's progress comes at a time of unprecedented excitement and investment in the radiopharmaceutical sector. The industry, which pairs diagnostic imaging with targeted radiation therapy in an approach known as "theranostics," is projected to grow exponentially, with some market forecasts predicting it could exceed $35 billion by 2034.

This boom is fueled by clinical successes and major acquisitions. In the past year, pharmaceutical giants have spent billions to acquire promising radiopharmaceutical companies, including Eli Lilly's purchase of Point Biopharma, Bristol Myers Squibb's acquisition of RayzeBio, and AstraZeneca's deal for Fusion Pharmaceuticals. These transactions underscore the immense value big pharma places on platforms that can deliver potent radiation directly to cancer cells while minimizing damage to healthy tissue.

With a diverse pipeline targeting validated and novel cancer pathways, a strong balance sheet, and a strategic partnership with a world-leading cancer institution, Radiopharm Theranostics is well-positioned to capitalize on this momentum. As the company prepares for a year packed with multiple data readouts and clinical trial initiations, it stands as a key innovator in a field poised to redefine cancer care.